KdT Podcast: CG Oncology
Cain McClary and Phil Grayeski unpack the first biotech IPO of 2024.
The World In A Grain of Sand by KdT Ventures
KdT is the standard in early-stage science-driven venture capital. We help founders and their companies re-architect the world at a molecular level.
Subscribe:.rss.atom.json.md.m3u.pls
Dormant Last read · last published · next check
Read 10 days ago and current, but nothing has been published for 2 years.
Latest episodes
Podcast: Verve Therapeutics
Ketan Yerneni and Mack Healy dig into a gene editing biotech tackling one of the most prevalent chronic diseases.
Podcast: Schrödinger
A deep dive into the science and business of the OG AI-driven drug discovery company
Who I am: Blair
As a firm, the team at KdT has decided to publish long-form biographies to help the folks we work with learn more about who we are as people.
Who I am: Yusuf
As a firm, the team at KdT has decided to publish long-form biographies to help the folks we work with learn more about who we are as people.
Who I am: Patrick
As a firm, the team at KdT has decided to publish long-form biographies to help the folks we work with learn more about who we are as people.
Podcast: Amylyx Pharmaceuticals
a neuro biotech founded in the dorm room of two scrappy Brown undergrads
Overscienced but Underfunded: Research Triangle, NC (Durham, Raleigh, Chapel Hill)
Impactful science and technology can be invented anywhere
Expanding the Drug Delivery Toolbox
Today our ability to treat many diseases is limited only by our ability to effectively deliver genetic medicines.
State of the Market: The Goalposts
Before I start, let me get two things out of the way.